Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
milnacipran + d-cycloserine
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of milnacipran, a selective serotonin and norepinephrine reuptake inhibitor (SNRI) with preferential inhibition of norepinephrine reuptake, and D-cycloserine, an NMDA receptor modulator. Milnacipran is FDA-approved for fibromyalgia management, while D-cycloserine has been investigated for various neuropsychiatric conditions. This specific combination is not well-documented in the literature provided.
- Other names
- Milnacipran and D-cycloserineD-cycloserine and Milnacipran
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on milnacipran + d-cycloserine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on milnacipran + d-cycloserine.